Stewart Campbell

	Stewart Campbell
	Stewart Campbell serves as Senior Vice President of Preclinical Research & Development for Axial Biotherapeutics in Boston, USA. He brings nearly 25 years of industry drug discovery and development experience, most recently in the area of translational research in neurodegenerative diseases and neurodevelopmental disorders. He has built and led R&D teams involved in a variety of environments from early stage research through to advanced clinical development in small start-ups to mid-sized companies. Prior to joining Axial, Dr. Campbell held various leadership roles at biopharmaceutical and chemical manufacturing companies including Corden Pharma, Surface Logix and Insmed Inc.
At Corden Pharma, Dr. Campbell served as Head of Product Management and Business Development for Carbohydrates and Lipids and as Head of Operations for Corden Pharma’s Woburn, MA manufacturing site. Prior to Corden Pharma Dr. Campbell served as Vice President of R&D at Ancora Pharmaceuticals, successfully triaging the company through the acquisition and integration process by Corden Pharma. While at Surface Logix and Insmed, Dr. Campbell played an integral role in the discovery and development of five clinical stage drug candidates, including small molecules and biotherapeutics. He holds a Ph.D. in Organic Chemistry from the Queen’s University (Canada), and conducted post-doctoral research in natural product synthesis at Duke University. He has consulted for several start-up companies in multiple technology and therapeutic areas in the Greater Boston area and is co-inventor on 17 issued patents.